Anthera Pharmaceuticals, which is developing anti-inflammatory therapeutics for cardiovascular diseases and lupus, announced terms for its IPO on Wednesday. The Hayward, CA-based company plans to raise $64 million by offering 4.6 million shares at a price range of $13-$15. At the mid-point of the proposed range, Anthera will command a market value of $242 million. Anthera Pharmaceuticals, which was founded in 2004 and has yet to generate product revenue, plans to list on the NASDAQ under the symbol ANTH. Deutsche Bank is the lead underwriter on the deal, for which timing was not disclosed.
